Purpose: We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I trial to evaluate the combination of paclitaxel with doxorubicin.
Introduction
Combination chemotherapy is the most effective systemic antineoplastic treatment for metastatic breast cancer which will kill an estimated 314,000 women worldwide in 1999 [1] . Arguably, doxorubicin is the most effective single agent against metastatic breast cancer. We and others have demonstrated superior antineoplastic activity of paclitaxel in metastatic breast cancer [2] [3] [4] . The next obvious strategy was to incorporate paclitaxel and doxorubicin in a combination regimen.
Patients and methods

Patient eligibility
Patients with histologically proven breast cancer with measurable or evaluable metastatic disease who had not received any prior chemotherapy for metastatic disease were eligible for this study. Measurable * Portions of this work have previously been presented orally and in abstract form at The Annual Meeting of the American Society for Clinical Oncology, May 1992. disease was defined as lesions that could be measured in two perpendicular dimensions either directly by visual inspection or palpation of the lesion or by imaging methods. Evaluable disease was defined as lytic bone disease measuring > 1 cm. Patients who had received adjuvant chemotherapy were eligible if they had not received doxorubicin or if they had adequate cardiac function and had relapsed > 6 months after completion of a doxorubicin-containing regimen with a cumulative total dose of < 301 mg/m 2 for doxorubicin administered by intravenous bolus or < 401 mg/m 2 for doxorubicin given by 48-hour or longer infusion. Adequate cardiac function for patients who had received prior anthracyclines or anthracenediones was specified as a left ventricular ejection fraction (LVEF) ^65% without wall motion abnormalities or a LVEF of 50%-64% but an endomyocardial biopsy score of grade < 1 [5] . Patients without prior exposure to cardiotoxic agents were required to have a LVEF of 3= 60%. Because of the risk of anaphylactoid reactions following the administration of paclitaxel, patients were not eligible if they had a history of significant cardiac disease, such as serious arrhythmias requiring antiarrhythmic medication, a history of myocardial infarction within the past six months, or Mobitz type II or third-degree atrioventricular conduction system abnormalities uncorrected by cardiac pacemaker. All patients were required to have a functioning central venous catheter.
Other eligibility criteria were the standard criteria for a phase I study. No other simultaneous chemotherapy, hormonal therapy, immunotherapy, or radiotherapy could be administered. Patients were required to have sufficient physiologic reserve to tolerate the toxic effects of therapy. This included life expectancy of 3= 12 weeks, Zubrod [6] performance status of <3, adequate hematologic reserve (absolute granulocyte count of ^ 1,500 cells/ul and a platelet count of 3= 100,000/ul); adequate hepatic function (serum bilirubin level <1.5 mg/ml); and adequate renal function (serum creatinine level <1.4 mg/ml).
Before treatment, all patients gave written informed consent according to institutional and federal guidelines. All patients were registered in our central data management office.
Pretreatment evaluation
Pretreatment evaluation included a complete history and physical examination; a complete blood count with differential and platelet counts (CBC), total protein, albumin, calcium, phosphorus, glucose, creatinine, blood urea nitrogen, bilirubin, alkaline phosphatase, lactase dehydrogenase. alanine aminotransferase (collectively referred to as SMA-12), electrolytes, magnesium, appropriate tumor marker studies (carcinoembryonic antigen [CEA], CA 15-3, or CA-125) and urinalysis; chest radiograph, computed tomography or ultrasonography of the abdomen: radionuclide bone scan followed by appropriate radiographs of affected bones; baseline electrocardiogram; and radionuclide cardiac scan with determination of LVEF. All studies were obtained within 30 days before entry into the study.
Treatment protocol
Chemotherapy
The starting doses for part 1 were paclitaxel 125 mg/m 2 over 24 hours followed by doxorubicin 60 mg/m 2 over 48 hours. On the basis of observations in the early stages of the study (hereafter referred to as part 1). we decided to reverse this schedule (hereafter referred to as part 2). The next patients enrolled in the study (those in part 2) received doxorubicin followed by paclitaxel. Because the MTDs were so different in parts 1 and 2, we studied the pharmacology of paclitaxel and doxorubicin in combination (hereafter referred to as part 3). Data from the pharmacology investigation have previously been reported [11] . Finally, in part 4 of the study, we administered doxorubicin as a bolus dose before paclitaxel during the first two cycles to see if this would allow administration of a higher dose of paclitaxel. However, the third and all subsequent courses in part 4 required administration of doxorubicin by 48-hour infusion, consistent with our standard of practice.
The starting doses of paclitaxel and doxorubicin in parts 2 and 3, and the third and all subsequent courses in part 4 were: paclitaxel 125 mg/m 2 and doxorubicin 48 mg/m 2 . The starting dose for the first two courses in part 4 were paclitaxel 160 mg/m 2 and doxorubicin 50 mg/m 2 . Standard premedication for paclitaxel was administered as previously reported [2] .
Dose escalation was conducted according to standard procedures for phase I clinical trials. Three patients were treated at each level. If no patient developed grade 3 or greater toxicity (excluding granulocytopenia) or dose-limiting granulocytopenia (as defined below), three patients were treated at the next dose level. If one of three patients developed grade 3 or greater toxicity or dose-limiting granulocytopenia (see below), three additional patients were entered on the same dose-level. If any three patients developed grade 3 toxicity or doselimiting granulocytopenia or any two patients developed grade 4 toxicity, that dose was defined as exceeding the maximum tolerated dose (MTD) and three additional patients were treated at the next lowest dose, for a total of six patients treated at the MTD. The MTD was thus defined by dose-limiting toxic effects experienced by patients treated at that dose level for their first course, not by toxic effects experienced by patients escalated to that dose level.
In view of the lack of complications associated with profound granulocytopenia alone in our initial phase II study of paclitaxel alone for metastatic breast cancer [2] , dose-limiting granulocytopenia was defined as fever suspected of bacterial or fungal origin; documented infection or sepsis with a granulocyte count of < 500/ul; a granulocyte count of < 250/ul for 3: 5 days; or failure to recover to a granulocyte count of 3= 1500/ul by day 22. A platelet count of < 20,000/ul at any time was also considered dose-limiting hematologic toxicity.
The dose escalation schedules for all parts (including the pharmacology study previously reported [7] ) are shown in Table 1 . All courses were repeated every 21 days or as soon thereafter as the patient had recovered to a granulocyte count of 3=1,500/ul, platelet count of > 100,000/ul, and all nonhematologic toxic effects had recovered to baseline or grade 1 as defined by the National Cancer Institute's (NCI's) Common Toxicity Criteria [8] . Filgrastim (human recombinant granulocyte colony-stimulating factor) 5 ug/kg, rounded to the nearest vial size of 300 ug or 480 ug, was administered subcutaneously from days 5 thru 19 or longer until the absolute granulocyte count was 5= 10,000/ul but not 3;25,000/ul. Therapy was continued for at least two courses unless there was rapidly progressive disease during treatment, and for at least three courses if there was no change in a MTD for part 2 (doxorubicin followed by paclitaxel). b MTD for part 1 (paclitaxel followed by doxorubicin). c Presumed MTD for part 4. No patients were treated at this dose level, but four patients treated at dose level 0 experienced dose-limiting neutropenic fever or neutropenia. fever, and bacteremia. disease and if intolerable (grade 3-4) toxicity was not seen. For patients whose disease evinced remission, treatment was to be continued for six courses after achieving maximum response. Patients who were clearly progressing before receiving treatment and who showed no change in disease after receiving treatment continued to receive the treatment until there was definite evidence of progressive disease, intolerable toxicity, or decrease in LVEF below 50% for a maximum of six cycles. Dose-limiting granulocytopenia required a one dose-level reduction. Two dose-level reductions were required for granulocytopenia accompanied by grade 4 infection. The first occurrence of grade 3 thrombocytopenia or the second occurrence of grade 2 thrombocytopenia required one dose-level reduction. Non-hematologic toxicities of grades 3 and 4, excluding alopecia (for which no accommodation was made), required one dose-level reduction.
Evaluation during treatment
Patients had a CBC at least once weekly. During treatment with filgrastim, the CBC was obtained three times a week. The SMA-12 was obtained before each course and as frequently as needed to define toxic effects. Tumor marker studies were repeated before each course if initially elevated. Radiographs, sonograms, or magnetic resonance imaging studies required for tumor measurement were repeated after two courses or to confirm a complete response or document progressive disease. Subsequently, these studies were repeated after every three or four courses unless the clinical situation required that they be performed sooner.
The intensity of cardiac evaluation decreased during the study as the lack of cardiac toxicity became obvious. Initially, cardiac evaluation consisted of 72-hour Holter monitoring during all courses for patients treated in part 1 and for the initial 13 patients in part 2. Continuous real time cardiac monitoring was performed in the Telemetry Unit for 72 hours during the first treatment in part 1. If no problems were encountered, all subsequent courses were given in the ambulatory treatment unit with Holter monitoring for 24 hours during the infusion of pachtaxel. All remaining patients in part 2 and all patients in parts 3 and 4 were treated as outpatients When experience revealed no evidence of rhythm disturbance, all patients were treated as out-patients without Holter monitoring. In all patients, follow-up radionuclide cardiac scans to determine LVEF were repeated after every course for patients who had previously received doxorubicin by bolus injection as part of adjuvant therapy. For patients whose previous doxorubicin had been given by 48-hour or longer infusions, the LVEF was determined after cumulative total doses of 450 mg/m 2 , 600 mg/m 2 and then after every course. Treatment was continued only if the LVEF was S=60%. If the LVEF was <60% but 5=50%, an endomyocardial biopsy was performed and graded according to previously published criteria [5] . A biopsy score of >1.5 or an LVEF < 50% mandated discontinuation of doxorubicin. For patients whose LVEF remained between 50% and 60% and who had no evidence of congestive heart failure, biopsies were repeated after every two courses.
Criteria for response and grading of toxic effects Standard criteria as defined by Hayward et al. [9] were used to grade response. The criteria for a complete response (CR) were stringently defined as as disappearance of all evidence of tumor for at least one course of therapy or four weeks, including normalization of bone scans and x-rays, complete disappearance all symptoms of cancer, and normalization of tumor markers. All responses were confirmed by the primary investigator and at least two other members of the Department of Breast Medical Oncology.
All toxic effects were graded according to the NCI's Common Toxicity Criteria [8] .
Statistical methods All patients treated were evaluable for both toxicity and response. Survival of patients was measured from the date of the first treatment Duration of response was measured from the first observation of the response. Time to progression was measured from the date of the first treatment until development of progressive disease. Survival, time to progression, and response duration were calculated using the KaplanMeier method [10] .
Results
Between August 1991 and February 1994, 38 patients were treated on parts 1, 2 and 4 of this study. Patient characteristics are shown in Table 2 . Ten additional patients, who were treated on the pharmacology portion of the study, conducted from January through October 1993 have been reported previously [7] . As in our previous studies, most patients in parts 1 and 2 were young, had visceral disease, and had two or more involved sites of disease. In part 4, however, patients tended to be older and have fewer sites of disease. A majority of patients, 29 of 48, had received adjuvant therapy, but in only a minority, 12 of those 29, did that regimen include doxorubicin. Of 12 patients who had received prior doxorubicin, four had CR, seven had PR, and one had a minor response (reported as no change). Of 17 patients who had received prior CMF adjuvant therapy, three had CR, seven had PR, six had minor responses (reported as no change), and one had progressive disease. The median time since completion of adjuvant therapy was 17 months (range 1-79).
MTDs
Of the initial cohort of three patients treated in part 1 with the schedule (paclitaxel 125 mg/m 2 followed by doxorubicin 60 mg/m 2 ), one patient experienced either grade 3 mucositis, one patient had neutropenic fever, and one patient had both. Three additional patients were treated at the same dose level; two of them developed neutropenic fever and one also had grade 3 mucositis. The second cohort of three patients was then treated at level -1 (paclitaxel 125 mg/m 2 and doxorubicin 48 mg/m 2 ). No patient experienced grade 3 toxic effects at this level so three additional patients were treated. These additional three patients also tolerated treatment without any grade 3 toxic effects, so this level was declared the MTD (Table 3) . One additional patient was erroneously treated with this schedule at an incorrect dose of paclitaxel 160 mg/m 2 over 24 hours followed by doxorubicin 60 mg/m 2 over 48 hours. She had liver metastases that had been rapidly progressing during the time required for activation of this study, but her bilirubin level remained normal, and the alanine aminotransferase level was only 1.5 times above the upper limit of normal. She experienced grade 3 or 4 mucositis for seven days and neutropenia with fever. Subsequent courses required dose reduction in the majority of patients, mostly owing a The pharmacokinetic study was conducted from January 1992 through October 1993 b Doxorubicin was given by bolus infusion only in courses 1 and 2. All subsequent courses were given by 48-hour infusion. c One patient had high-dose chemotherapy with stem-cell rescue after induction with doxorubicin followed by paclitaxel.
to cumulative thrombocytopenia. This finding was unexpected because cumulative thrombocytopenia did not occur in our previous experience with single-agent paclitaxel [2] . Other toxic effects by grade and sequence of administration are shown in Table 4 .
The observation of such significant mucosal and hematologic toxicity was not anticipated. A concurrent study at NCI by Fisherman et al. using simultaneous administration of paclitaxel and doxorubicin over 72 hours had already escalated to much higher doses without these effects [11] . We hypothesized a schedule-dependent interaction was occurring and we decided to evaluate the reverse schedule in part 2. The MTD established in part 1 (doxorubicin 48 mg/m 2 over 48 hours followed by paclitaxel 125 mg/m 2 over 24 hours) was used as the starting dose for part 2. Dose-limiting neutropenic fever occurred at dose level 2 (doxorubicin 60 mg/m 2 over 48 hours followed by paclitaxel 180 mg/m 2 over 24 hours), so the MTD was declared to be doxorubicin 60 mg/m 2 over 48 hours followed by paclitaxel 150 mg/m 2 over 24 hours.
Part 3 was a pharmacokinetic study which evaluated the effect of sequence of paclitaxel and doxorubicin on doxorubicin levels in 10 patients [7] . For courses 1 for each patient, the sequence of drugs was reversed, thus making each patient her own control. Doxorubicin levels were increased by an average of 70%, and, conversely, doxorubicin clearance was decreased by a mean of 32% when paclitaxel by 24-hour infusion preceded doxorubicin by 48-hour infusion. These increased levels of doxorubicin resulted in the expected sequella: increased mucositis, neutropenia, and fever compared to the reverse sequence. These toxic effects were solely the consequence of the sequence of drug administration when paclitaxel and doxorubicin were administered by 24-and 48-hour infusions, respectively. Because administration of doxorubicin by bolus is more common, we attempted to define the MTD of bolus doxorubicin with paclitaxel by 24-hour infusion in part 4. Doxorubicin was administered by bolus in the first two courses only to determine the MTD. The MTD from part 2 was used for subsequent courses to continue treatment. Of seven patients treated at level 0, with bolus doxorubicin, two patients had fever with positive blood cultures and 2 had neutropenic fever. We did not further define the MTD with this schedule. However, the Eastern Cooperative Group trial El 193, comparing paclitaxel to doxorubicin to the combination of both drugs observed that paclitaxel 150 mg/m 2 over 24 hours with doxorubicin 50 mg/m 2 by bolus with G-CSF could be administered safely [12] .
A consistent finding across all three studies was cumulative thrombocytopenia necessitating dose reduction with continued treatment. Irrespective of the change in schedule of administration of doxorubicin in part 3, from bolus in courses 1 and 2 to 48-hour infusion in the third and all subsequent courses, thrombocytopenia was observed in courses 3 and beyond. The median nadir platelet values (and the ranges) for the six patients who completed courses 3 thru 6, respectively, were (x 10 
Cardiac toxic effects
Acute. Preliminary data on cardiac toxic effects in the initial seven patients have been reported [13] . Baseline ambulatory electrocardiographic recordings (Holter monitors) were reviewed from 22 of the initial 23 patients. Only three of these 22 patients (14%) had ectopyfree baseline Holter studies. Six patients (27%) had either nonsustained supraventricular tachycardia or complex ventricular ectopy on the baseline evaluation. Both real-time monitoring and ambulatory electrocardiographic monitoring were obtained over 72 hours during the infusions of paclitaxel and doxorubicin and the initial 1752 hours of recorded data in 23 patients were analyzed. The only observed abnormalities were a slowing of the mean heart rates from a range of 78 to 108 beats per minute baseline to a range of 48 to 101 beats per minute during paclitaxel infusion. A significant increase in atrial ectopic activity was also noted during the paclitaxel infusion. However, the available data are not sufficient to determine whether this was a sampling artefact because there was only one pretreatment Holter recording, but there were many additional Holter recordings during therapy. Moreover, with rare exceptions, there was no change in the frequency or complexity of ventricular ectopy with either doxorubicin or paclitaxel. There were no sustained bradyarrhythmias, tachyarrhythmias, or conduction disturbances, and no patient experienced any cardiac symptoms.
The first patient treated in this study, a 62-year-old woman who experienced a near complete remission in retrosternal, sternal, and mediastinal disease, experienced a dramatic increase in the number of premature ventricular contractions, from her baseline of 2.6 to 5.1 per hour during courses 1 through 4, to 164 per hour during paclitaxel infusion in course 5 and to 128 beats per hour during the first 24 hours of the doxorubicin infusion. Owing to a malfunction in the recording device, data from the last 24 hours of the doxorubicin infusion (hours 25 through 48) were lost. The patient had no symptoms during this time and was evaluated by our cardiologist (H.G.) who found normal results on cardiac evaluation. The patient received course six without any symptoms, and her ambulatory electrocardiographic recording during course six was similar to the baseline recordings.
Chronic. Median cumulative doses of doxorubicin by study are shown in Table 3 . The overall median cumulative total dose of doxorubicin for the entire group of 48 patients was 518 mg/m 2 (range 96 to 870). Thirty-two patients received 5=450 mg/m 2 , and the median cumulative dose in that group of 32 patients was 550 mg/m 2 . Twelve patients received ^ 600 mg/m 2 doxorubicin. Two patients developed congestive heart failure. The first patient had a cumulative total dose of 870 mg/m 2 of doxorubicin. The patient was treated on part 4 of the study and received courses 1 and 2 of doxorubicin (totaling 100 mg/m 2 ) by bolus injection. The remaining 745 mg/m 2 of doxorubicin had been given by 48-72-hour infusion. Signs of congestive heart failure developed 24 months after completion of doxorubicin and were managed medically until she died of pulmonary and pericardial metastases three months later. No cardiac biopsy was performed. The second patient had a cumulative total of 660 mg/m 2 of doxorubicin given by 48-hour infusion on part 2. There were no known risk factors for cardiac toxicity. The LVEF was normal after course 10, totaling 600 mg/m 2 doxorubicin, but a routine cardiac biopsy was inadequate for evaluation. She received course 11, completing 660 mg/m 2 doxorubicin. One month later, she developed acute congestive heart failure requiring hospitalization but became asymptomatic with standard medical management. LVEF was 32% with normal wall motion when she was seen at M.D. Anderson four months later with newly recurrent metastatic disease.
A total of 222 cardiac scans were performed on 48 patients. In addition, 17 echocardiograms were done to evaluate unexpected decreases in the LVEF as determined by isotope scan. In six patients (13%) the LVEF decreased by ^15%, however in four of these six the final value was still above the normal of 50% and was reported as normal. These significant drops, ranging from 16% to 27%, occurred at a time when the software for the isotope cardiac scans was being upgraded and the new limits of normal were changed from 65 ± 5% to 50 ± 5%. Thus, we judged that only two patients (4%) had a 'significant' drop in the LVEF. However, a total of six patients had a decrease in the LVEF to < 50%. Five of these patients had one or more endomyocardial biopsies. Three had grade 1.0 changes. A fourth patient had 'minor changes' in the endomyocardial biopsy after 10 courses, but a repeat biopsy after course 11 was normal. The fifth patient was the second patient who developed acute congestive heart failure described above.
Response rates and durations, survival, and time to progression
For the entire cohort of 48 patients, the response rates were: complete, 15%; partial, 54% (objective response rate, 69%, 95% CI: 54%-81%); minor and no change, 29%. Only one patient (2%) progressed. The median follow-up of living patients is 38+ months (range 20+-62+). The median response duration is seven months (range 1.8-33.7+), The median survival is 20.5 months (range 5-54+). The median time to progression is 9.6 months (range 1-33.7+). Note that this was a phase I trial and response rates were not an end point. However, response rates were expected to be high because most patients had limited prior therapy and both paclitaxel and doxorubicin have high antineoplastic activity.
Responses were similar in all four separate parts of the study. Of the 10 patients in part 1, one patient had a CR, seven patients had a PR, and two patients had NC. One of these two patients who had no change (minor response) after 11 treatments had a solitary pulmonary lesion that was subsequently resected and proved to be a bronchioalveolar cell cancer. Of the 21 patients in part 2, one patient had a CR, 13 patients had a PR, seven patients had NC. Of 10 patients in part 3, two patients had a CR, and four each had PR and NC. In part 4, three patients had a CR, one of which is ongoing in the liver at 58+ months, two patients had a PR, and one patient each had NC and PD. Of the entire group of 48 patients, one remains in CR at 62+ months, one is alive with disease, and two are lost to follow-up with progressive disease and presumed dead.
Discussion
Our study determined the MTDs for the sequential combination of paclitaxel by 24-hour infusion and doxorubicin by 48-hour infusion and observed that the MTDs were sequence-dependent. The MTDs for paclitaxel over 24 hours followed by doxorubicin over 48 hours were 125 mg/m 2 for paclitaxel and 48 mg/m 2 for doxorubicin. For the reverse sequence, the MTDs were 150 mg/m 2 for paclitaxel and 60 mg/m 2 for doxorubicin. When we tested the combination of bolus doxorubicin with paclitaxel by 24-hour infusion, we found that our starting dose was too toxic and did not further pursue the MTD. Despite the use of filgrastim, neutropenic fever, with or without mucositis, was the dose-limiting toxic effect. Cumulative thrombocytopenia occurred. Other toxic effects, including cardiac, were minimal. Only two patients had congestive heart failure at cumulative doxorubicin doses of 870 and 660 mg/m 2 . We designed the protocol to determine the MTD with 409 the use of fllgrastim in hopes of rapidly translating this regimen's expected high complete response rates into the phase II setting. As expected, response rates for all sequences were high. However, these response rates were not greater than response rates previously reported for our standard combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) [14] [15] [16] . The occurrence of CR and the duration of responses did not differ between this trial and our previous FAC trials [16] . This suggests that the schedule of paclitaxel and doxorubicin that we used for the present study is not optimal. In part 4, the CR rate was higher (43%) than in the other parts, but only seven patients were treated and the 95% CI for this response, 29% to 96%, is still within the ranges of response for standard FAC treatment because the sample size is so small.
Concurrent with this study the NCI [11] and, subsequently, Indiana University [17] evaluated two other infusion schedules with paclitaxel and doxorubicin. Objective responses and durations of response were similar to those in ours. In the NCI trial, considerably more toxic effects were accepted. For example, the occurrence of neutropenic fever did not mandate immediate dose reduction. A consequence of this was that more patients required platelet transfusion (8% of 296 courses) as cumulative thrombocytopenia developed. The novel 72-hour simultaneous infusion schedule was associated with a potentially lethal toxic effect, neutropenic enterocolitis or typhlitis [18] . Congestive heart failure was not a reported toxic effect, presumably because of the prolonged infusion schedule of doxorubicin.
During our study, Hahn et al. published results of in vitro assays of cell kill of MCF-7 human breast cancer cells using doxorubicin alone or in the presence of paclitaxel [19] . They found schedule-dependent results. Concurrent use of paclitaxel and doxorubicin reduced cell kill compared to doxorubicin alone. Sequential use of doxorubicin for one hour followed by paclitaxel for 24 hours caused less than additive cytotoxicity for the combination. In contrast, subsequent studies in at M.D. Anderson by Madden et al., showed enhanced cell kill with the combination of paclitaxel and doxorubicin [20] . Because of the poorly understood interactions inherent in the complex biologic system of the entire human organism, testing of paclitaxel and doxorubicin in combination was reasonable despite the predictions from cell culture studies.
After the disappointing results noted in both our and the NCI's trials of this combination using paclitaxel by 24-hour infusion, Gianni et al. reported a 94% objective response rate (95% CI: 79%-99%) and a CR rate of 41% [21] . They had treated 29 evaluable women, who had not received any prior chemotherapy, with doxorubicin by bolus injection followed by paclitaxel by three-hour infusion. Other than the lack of any prior chemotherapy, their patients with metastatic breast cancer appeared representative of those in most studies: The median age was 50 years, 56% had visceral-dominant disease, and 66% had three or more disease sites. However, the median duration of responses (eight months for CRs and 11 months for PRs after a median follow-up of 12 months) were not superior to those seen with standard FAC combinations, and excessive cardiac toxicity was noted at unusually low cumulative doses of doxorubicin. At the last report, 7 of 34 patients (21%) had developed reversible congestive heart failure.
Gehl et al. performed a confirmatory trial in 29 evaluable women nine of whom had received prior adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) [22] . The CR rate was 25%; the objective response was 83% (95% CI: 79%-99%), and the median duration of response was only nine months (range 4-22+). The incidence of congestive heart failure was also 21% (six patients), however 15 of 30 patients evaluable for toxicity (50%, 95% CI: 31%-69%) had an abnormal LVEF at least once during treatment. Both Gianni et al. and Gehl et al. reported that the incidence of cardiac complications of any sort were minimal if the total cumulative dose of doxorubicin were limited to 360mg/m 2 .
The trials by Gianni et al. and Gehl et al. demonstrated the high response rates we had hoped from the combination of paclitaxel and doxorubicin. However, a number of other studies have evaluated the combination of paclitaxel with anthracyclines or anthracendiones [23] [24] [25] [26] [27] [28] [29] and most of these have not replicated those encouraging results of Gianni et al. Sledge et al. reported the results of the completed Intergroup (a collaboration among the Eastern Cooperative Oncology Group (ECOG), the North Central Cancer Treatment Groups, and the Southwest Oncology Group (SWOG)) trial (El 193) using paclitaxel 200 mg/m 2 by 24-hour infusion versus doxorubicin at 60 mg/m 2 by bolus versus the combination of doxorubicin 50 mg/m 2 by bolus injection followed by paclitaxel 150 mg/m 2 by 24-hour infusion for the initial chemotherapy for women with metastatic breast cancer who may or may not have received adjuvant therapy [12] . Of 683 evaluable patients, objective response rates were 36% and 34% for the single agents doxorubicin and paclitaxel, respectively, and 47% for the combination. However, the complete response rates were only 6% and 3%, respectively for doxorubicin and paclitaxel, and 9% for the combination. Median survival time was not significantly different among the three arms after crossover. Hortobagyi et al. at M.D. Anderson have completed a randomized trial of bolus doxorubicin followed by paclitaxel by one or three-hour infusion [30] . Patients had serial LVEF determinations and endomyocardial biopsies. This trial was designed to provide sufficient power to evaluate the efficacy of the combination as well as to define the cardiotoxicity of the regimen. The preliminary results of cardiac biopsies on seven patients who have completed 360 mg/m 2 showed four patients had grade 1.0 changes, two had grade 0.5 changes, and one had grade 0 changes. These confirmed the safety of this regimen if the doses of doxorubicin are limited to 360 mg/m 2 . Data on efficacy were not reported. D'lncalci et al. have reviewed the pharmacokinetic considerations of the combination of taxoids with anthracyclines. A striking observation is that the administration of paclitaxel following epirubicin by short intravenous infusion produced a near doubling of the epirubicin levels within the myocardium! [31] . An increase of the intramyocardial levels of anthracyclines is the proposed explanation for the unexpectedly high incidence of cardiac dysfunction seen in these trials.
Since this study has been completed, many additional studies have been performed to optimize the combination of taxoids and anthracyclines. Based on evidence such as discussed by D'lncalci et al. [31] , as well as the initial in vitro studies of docetaxel [32] , it appears that, of the currently available taxoids, docetaxel is the preferred agent for combination therapy. Nabholtz et al.'s preliminary reports of a phase III randomized trial comparing doxorubicin and cyclophosphamide to doxorubicin with docetaxel suggest that a new standard of care may soon be established [33] .
